Compare

Side-by-side tables built from each drug's own trials and labels. Different trials enrolled different people for different lengths of time, so read every cross-trial row as context, not a head-to-head result.

Updated by the GLP Ladder Editorial Team. Editorial policy.

Comparisons

  • Foundayo vs Wegovy Pill

    Foundayo vs Wegovy pill from the FDA labels: dose ladders, food and water rules, missed doses, half-life, trial results and who each pill is approved for.

  • GLP-3 vs GLP-1

    GLP-3 is not a hormone or a drug class

  • Mounjaro vs Zepbound

    Mounjaro vs Zepbound from the FDA labels: same tirzepatide, different indications, one 2.5 to 15 mg ladder, pens and vials, storage, trials and coverage.

  • Ozempic vs Wegovy

    Ozempic vs Wegovy from the FDA labels: one molecule, different indications, dose ladders (2 mg vs 2.4 and 7.2 mg), pens, pills, missed-dose rules and switching.

  • Retatrutide vs Semaglutide

    Retatrutide vs semaglutide side by side: receptor targets, approval status, half-life, dose ladders, TRIUMPH-1 vs STEP 1 weight results and side-effect rates.

  • Retatrutide vs Tirzepatide vs Semaglutide Compared

    Retatrutide vs tirzepatide vs semaglutide in one table: receptor targets, status, half-life, dose ladders, pivotal trial results and side-effect rates.

  • Retatrutide vs Tirzepatide

    Retatrutide vs tirzepatide side by side: receptor targets, approval status, half-life, dose ladders, TRIUMPH-1 vs SURMOUNT-1 results and side-effect rates.

  • Tirzepatide vs Semaglutide

    Tirzepatide vs semaglutide compared: SURMOUNT-5 head-to-head results, SURPASS-2 in diabetes, label dose ladders, half-lives and side-effect rates.

  • Wegovy vs Zepbound

    Wegovy vs Zepbound from the FDA labels: indications, dose ladders, pens and vials, storage, missed doses, SURMOUNT-5 results and Oct 2026 self-pay prices.